The main objective of this document is to provide technical recommendations for the detection and differentiation
of wild-type and/or vaccine dengue virus (DENV) in people who have received the TAK-0031 (Qdenga®) vaccine and who present symptoms compatible with a DENV infection (1) within 30 days after having received a dose of the vaccine (first or second dose). For other dengue vaccines that are of the same type (live attenuated virus vaccines), the same diagnostic recommendations apply. Likewise, this document will be reviewed and updated when new biologics, new clinical trials with additional evidence, or new diagnostic platforms are available and should be considered. |
